Subtopic Deep Dive
High-Density Lipoprotein Functionality
Research Guide
What is High-Density Lipoprotein Functionality?
High-Density Lipoprotein Functionality refers to HDL's biological activities including cholesterol efflux capacity, anti-inflammatory effects, and reverse cholesterol transport efficiency, independent of HDL-C concentration levels.
HDL functionality assessment focuses on proteome changes in dyslipidemia and therapeutic enhancements to HDL quality (von Eckardstein et al., 2022; 317 citations). Research highlights dysfunctional HDL's role in residual cardiovascular risk despite LDL lowering. Over 300 papers since 2007 explore these metrics, with key works exceeding 280 citations.
Why It Matters
Dysfunctional HDL drives atherosclerosis progression and incident cardiovascular events, as shown in prospective studies linking enhanced cholesterol efflux paradoxically to higher risks (Li et al., 2013; 297 citations). Therapies targeting HDL quality, unlike HDL-C raisers like torcetrapib, failed due to off-target effects increasing mortality (Tall et al., 2007; 269 citations). HDL proteomics in sepsis reveals protective shifts, informing interventions for acute cardiovascular complications (Tanaka et al., 2020; 248 citations). These insights guide precision therapies beyond statins.
Key Research Challenges
HDL-C vs Functionality Disconnect
HDL-C levels inversely correlate with CVD in epidemiology but fail to predict risk in trials (von Eckardstein et al., 2022; 317 citations). Genetic and RCT evidence questions HDL-C as causal protector (Rader and Tall, 2012; 269 citations). Metrics like efflux capacity show paradoxical associations with events (Li et al., 2013; 297 citations).
Therapeutic HDL Enhancement Failures
CETP inhibitors like torcetrapib raised HDL-C but increased mortality via hypertension and aldosterone effects (Tall et al., 2007; 269 citations). Infusion therapies improve efflux but lack outcome data (Rohatgi et al., 2021; 302 citations). Identifying safe modulators remains unresolved.
Assessing HDL Proteome Dynamics
HDL proteome varies in dyslipidemia and sepsis, affecting anti-inflammatory roles (Tanaka et al., 2020; 248 citations). Standardizing efflux and oxidation assays across cohorts challenges reproducibility (März et al., 2017; 280 citations). Sepsis-induced shifts complicate functionality metrics.
Essential Papers
Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke
Michael V. Holmes, Iona Y. Millwood, Christiana Kartsonaki et al. · 2018 · Journal of the American College of Cardiology · 482 citations
High-density lipoprotein revisited: biological functions and clinical relevance
Arnold von Eckardstein, Børge G. Nordestgaard, Alan T. Remaley et al. · 2022 · European Heart Journal · 317 citations
Abstract Previous interest in high-density lipoproteins (HDLs) focused on their possible protective role in atherosclerotic cardiovascular disease (ASCVD). Evidence from genetic studies and randomi...
HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research
Anand Rohatgi, Marit Westerterp, Arnold von Eckardstein et al. · 2021 · Circulation · 302 citations
Low high-density lipoprotein cholesterol (HDL-C) characterizes an atherogenic dyslipidemia that reflects adverse lifestyle choices, impaired metabolism, and increased cardiovascular risk. Low HDL-C...
Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities
K Mahdy Ali, Anna Wonnerth, Kurt Huber et al. · 2012 · British Journal of Pharmacology · 301 citations
Since the first discovery of an inverse correlation between high‐density lipoprotein‐cholesterol (HDL‐C) levels and coronary heart disease in the 1950s the life cycle of HDL, its role in atheroscle...
Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks
Xin-Min Li, W.H. Wilson Tang, Marian Mosior et al. · 2013 · Arteriosclerosis Thrombosis and Vascular Biology · 297 citations
Objective— Diminished cholesterol efflux activity of apolipoprotein B (apoB)–depleted serum is associated with prevalent coronary artery disease, but its prognostic value for incident cardiovascula...
HDL cholesterol: reappraisal of its clinical relevance
Winfried März, Marcus E. Kleber, Hubert Scharnagl et al. · 2017 · Clinical Research in Cardiology · 280 citations
The Failure of Torcetrapib
Alan R. Tall, Laurent Yvan‐Charvet, Nan Wang · 2007 · Arteriosclerosis Thrombosis and Vascular Biology · 269 citations
Reading Guide
Foundational Papers
Start with Rader and Tall (2012; 269 citations) for HDL hypothesis revision, Tall et al. (2007; 269 citations) on torcetrapib failure, and deGoma et al. (2008; 255 citations) on metrics beyond HDL-C to grasp core shifts.
Recent Advances
Study von Eckardstein et al. (2022; 317 citations) for clinical relevance, Rohatgi et al. (2021; 302 citations) for multifunctional roadmap, and Tanaka et al. (2020; 248 citations) for sepsis applications.
Core Methods
Core techniques: cholesterol efflux via J774 macrophages (Li et al., 2013), HDL proteomics by mass spectrometry (Tanaka et al., 2020), and RCT analysis of CETP modulators (Tall et al., 2007).
How PapersFlow Helps You Research High-Density Lipoprotein Functionality
Discover & Search
Research Agent uses searchPapers and citationGraph to map 482-cited Holmes et al. (2018) connections to HDL metrics in MI/stroke risk, then exaSearch for 'HDL efflux capacity dyslipidemia' yielding von Eckardstein et al. (2022). findSimilarPapers expands from Rohatgi et al. (2021; 302 citations) to 50+ functionality studies.
Analyze & Verify
Analysis Agent applies readPaperContent to extract efflux assays from Li et al. (2013), verifies paradoxical risk claims via CoVe against Rader/Tall (2012), and runs PythonAnalysis on HDL-C datasets for correlation stats with GRADE scoring for evidence strength in torcetrapib failures (Tall et al., 2007).
Synthesize & Write
Synthesis Agent detects gaps in HDL proteome therapies post-2022 via contradiction flagging between von Eckardstein (2022) and older CETP trials; Writing Agent uses latexEditText, latexSyncCitations for Rohatgi (2021), and latexCompile for review manuscripts with exportMermaid for RCT failure flowcharts.
Use Cases
"Correlate HDL efflux capacity datasets from cohort studies with CVD outcomes"
Research Agent → searchPapers('HDL efflux capacity') → Analysis Agent → runPythonAnalysis(pandas correlation on Li 2013 + Holmes 2018 data) → matplotlib plots + statistical p-values output.
"Draft LaTeX review on HDL functionality paradoxes citing 10 key papers"
Synthesis Agent → gap detection → Writing Agent → latexEditText(structure) → latexSyncCitations(von Eckardstein 2022 et al.) → latexCompile → PDF with diagrams.
"Find GitHub repos analyzing HDL proteome from recent papers"
Research Agent → citationGraph(Rohatgi 2021) → Code Discovery (paperExtractUrls → paperFindGithubRepo → githubRepoInspect) → verified analysis scripts for sepsis HDL shifts (Tanaka 2020).
Automated Workflows
Deep Research workflow scans 50+ HDL papers via searchPapers → citationGraph → structured report on functionality metrics (von Eckardstein 2022). DeepScan's 7-step chain verifies torcetrapib paradoxes (Tall 2007) with CoVe checkpoints and Python stats. Theorizer generates hypotheses on HDL proteome in dyslipidemia from Rohatgi (2021) + März (2017).
Frequently Asked Questions
What defines HDL functionality beyond HDL-C?
HDL functionality includes cholesterol efflux, anti-inflammatory properties, and reverse transport efficiency, assessed via apoB-depleted serum assays (Rohatgi et al., 2021; von Eckardstein et al., 2022).
What are key methods for HDL functionality?
Methods encompass cholesterol efflux capacity assays, proteome profiling, and oxidation metrics; efflux uses apoB-depleted serum on macrophages (Li et al., 2013; März et al., 2017).
What are landmark papers on HDL functionality?
von Eckardstein et al. (2022; 317 citations) reviews functions; Li et al. (2013; 297 citations) shows efflux paradoxes; Rohatgi et al. (2021; 302 citations) maps 21st-century metrics.
What open problems exist in HDL research?
Challenges include standardizing proteome assays, resolving CETP failures (Tall et al., 2007), and validating efflux for risk prediction beyond HDL-C (Rader and Tall, 2012).
Research Lipoproteins and Cardiovascular Health with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching High-Density Lipoprotein Functionality with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.